CYP19A1 and atherosclerosis: Olezarsen, ARO-APOC3 and especially ARO-ANG3 have also a mechanistic potential to reduce the risk of ASCVD in patients with HTG but such studies need to be performed separately with the respective endpoints; they are already underway with olezarsen.